Larimar Therapeutics, Inc.
LRMR
$3.44
-$0.06-1.71%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 27.68% | 3.79% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -51.39% | 29.33% | |||
| Operating Income | 51.39% | -29.33% | |||
| Income Before Tax | 52.62% | -30.99% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 52.62% | -30.99% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 52.62% | -30.99% | |||
| EBIT | 51.39% | -29.33% | |||
| EBITDA | 51.43% | -29.39% | |||
| EPS Basic | 55.28% | -20.44% | |||
| Normalized Basic EPS | 55.28% | -20.46% | |||
| EPS Diluted | 55.28% | -20.44% | |||
| Normalized Diluted EPS | 55.28% | -20.46% | |||
| Average Basic Shares Outstanding | 5.96% | 8.76% | |||
| Average Diluted Shares Outstanding | 5.96% | 8.76% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||